Table 3.
Cancers | Treatment regimen |
Year reported |
No. of patients | Responses | Reference |
---|---|---|---|---|---|
T-NHL, AML, SPL and MM |
Haploidentical γδ T lymphocytes, Zoledronate, and IL-2 |
2014 | T-NHL(1 pt), AML (1 pt), SPL(1), MM(1 pt) |
CR expect for MM pt which was not evaluable |
(161) |
Colorectal Cancer |
Zoledronate- activated, ex vivo-expanded Vγ9Vδ2 T cells |
2013 | 6 pts | CR was observed in one pt |
(162) |
RCC, Melanoma and AML |
Bisphosphonate- reactive γδ T lymphocytes, Low-dose IL-2 and Zoledronate |
2012 | RCC(7 pts), Melanoma(6 pts), AML(8 pts) |
No objective response for RCC and Melanoma pts, PD for 2 AML pts |
(163) |
IL-2 and Zoledronate - activated Vγ9Vδ2 T celle and |
2011 | Melanoma (pts), Ovarian cancer (2 pts), Cervical cancer(1 pt), Colon cancer (3 pts), Breast cancer (2 pts), Duodenal cancer (1 pt), Cholangiocarcino ma (1), Adenocarcinoma (1 pt), |
Melanoma: PD (4 pts), SD (2 pts), NE(1 pt); Ovarian cancer: PD (1 pt), SD (1 pt); Cervical cancer: PD; Colon cancer: PD (3 pts); Breast Cancer: PD(1 pt), CR (1 pt); Duodenal cancer: PD; Cholangiocarcino ma: PD; Adenocarcinoma: PD |
(148) | |
ALL and AML |
Allogeneic HSCT depleted of αβT cells |
2007 | ALL(77 pts), AML(76 pts) |
CR in 36 patients | (118) |
T-NHL, T cell non-Hodgkin lymphoma; AML, acute myeloid leukemia; SPL, secondary plasma cell leukemia; MM, multiple myeloma; RCC, Renal cell carcinoma; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplant; CR, complete response; PD, progressive disease; SD, stable disease; Pt(s), patient(s).